Evidence map›Paper›PMID 21297224›Full record

ArticleOncotarget2010

Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion.

Sepi Mahooti, Kyle Porter, Mary L Alpaugh, Yin Ye, Yi Xiao, Susie Jones, Joseph D Tellez, Sanford H Barsky

Abstract read
In one paragraph

Article in Oncotarget, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sepi MahootiDepartment of Pathology and Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio 43210.
Kyle PorterCenter for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio 43210.
Mary L AlpaughMemorial Sloan-Kettering Cancer Center, New York, NY 10065.
Yin YeUniversity of Nevada School of Medicine, Reno, NV 89557.
Yi XiaoDepartment of Pathology and Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio 43210.
Susie JonesDepartment of Pathology and Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio 43210.
Joseph D TellezUniversity of Nevada School of Medicine, Reno, NV 89557.
Sanford H BarskyUniversity of Nevada School of Medicine, Reno, NV 89557.

Funding

Informatics methods for identifying breast cancer control genes and proteinsR01CA141090 · NCI · OHIO STATE UNIVERSITY · PI CATALYUREK, UMIT V., HUANG, KUN · 2009 to 2013
$2.2M
THE DESMOPLASTIC RESPONSE TO TUMOR INVASIONR01CA040225 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARSKY, SANFORD HOWARD · 1985 to 1994
–
NOVEL MYOEPITHELIAL CELL LINE TO SUPPORT 1 BREAST CR03CA071195 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARSKY, SANFORD HOWARD · 1996 to 1997
–
NCI NIH HHS CA01351NCI NIH HHS CA40225NCI NIH HHS CA71195NCI NIH HHS R01 CA141090
6 · The paper itself

Abstract

The canonical view of the origin of tumor lymphovascular emboli is that they usually originate from lymphovascular invasion as part of a multistep metastatic process. Recent experimental evidence has suggested that metastasis can occur earlier than previously thought and we found evidence that tumor emboli formation can result from the short-circuiting step of encircling lymphovasculogenesis. Experimentally, we used a xenograft of human inflammatory breast cancer (MARY-X), a model that exhibited florid tumor emboli, to generate tumoral spheroids in vitro. In observational studies, we chose human breast carcinoma cases where there appeared to be a possible transition of in situ carcinoma to lymphovascular emboli without intervening stromal invasion. These cases were studied by morphometry as well as IHC with tumor proliferation (Ki-67) and adhesion (E-cadherin) markers, myoepithelial (p63), as well as endothelial (podoplanin [D2-40], CD31, VEGFR-3, Prox-1) markers. Unlabelled spheroids coinjected with either GFP or RFP-human myoepithelial cells or murine embryonal fibroblasts (MEFs) gave rise to tumors which exhibited GFP/RFP immunoreactivity within the cells lining the emboli-containing lymphovascular channels. In vitro studies demonstrated that the tumoral spheroids induced endothelial differentiation of cocultured myoepithelial cells and MEFs, measured by real time PCR and immunofluorescence. In humans, the in situ clusters exhibited similar proliferation, E-cadherin immunoreactivity and size as the tumor emboli (p =.5), suggesting the possibility that the latter originated from the former. The in situclusters exhibited a loss (50%-100%) of p63 myoepithelial immunoreactivity but not E-cadherin epithelial immunoreactivity. The tumor emboli were mainly present within lymphatic channels whose dual p63/CD31, p63/D2-40 and p63/VEGFR-3 and overall weak patterns of D2-40/CD31/VEGFR-3 immunoreactivities suggested that they represented immature and newly created vasculature derived from originally myoepithelial-lined ducts. Collectively both experimental as well as observational studies suggested the possibility that these breast cancer emboli resulted from encircling lymphovasculogenesis rather than conventional lymphovascular invasion.

Indexed as

AnimalsAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCadherinsCell DifferentiationEndothelium, VascularEpithelial CellsFemaleFluorescent Antibody TechniqueHumansKi-67 AntigenLymphatic VesselsMammary Neoplasms, ExperimentalMembrane ProteinsMiceAntigens, NeoplasmBiomarkers, TumorCadherinsCKAP4 protein, humanKi-67 AntigenMembrane ProteinsPlatelet Endothelial Cell Adhesion Molecule-1

Identifiers

PMID21297224
PMCPMC3058877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.